<SEC-DOCUMENT>0001110803-23-000003.txt : 20230111
<SEC-HEADER>0001110803-23-000003.hdr.sgml : 20230111
<ACCEPTANCE-DATETIME>20230110190613
ACCESSION NUMBER:		0001110803-23-000003
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20230109
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230111
DATE AS OF CHANGE:		20230110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ILLUMINA, INC.
		CENTRAL INDEX KEY:			0001110803
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				330804655
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0101

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35406
		FILM NUMBER:		23522261

	BUSINESS ADDRESS:	
		STREET 1:		5200 ILLUMINA WAY
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		8582024500

	MAIL ADDRESS:	
		STREET 1:		5200 ILLUMINA WAY
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ILLUMINA INC
		DATE OF NAME CHANGE:	20000331
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ilmn-20230109.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:8b48f99a-e037-4ffb-98e5-fea41bbc6a7b,g:8aa18fbb-c04f-4d51-b673-e25049429cb3,d:dd34d28522d445078041d2fa117c4005--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ilmn-20230109</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV80L2ZyYWc6YTI4MTc2NjI5OTg0NDc2ODg2YzAzNDc5MmI1YmVjNGMvdGFibGU6MzRkMGE2ZTEwYTQwNDk5OWFlMGFhMDQwNzNjMTI4MzEvdGFibGVyYW5nZTozNGQwYTZlMTBhNDA0OTk5YWUwYWEwNDA3M2MxMjgzMV8xLTEtMS0xLTE2MjQyNg_ea8e49d4-143f-40fa-a276-b23c3fc0ee7b">0001110803</ix:nonNumeric><ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV80L2ZyYWc6YTI4MTc2NjI5OTg0NDc2ODg2YzAzNDc5MmI1YmVjNGMvdGFibGU6MzRkMGE2ZTEwYTQwNDk5OWFlMGFhMDQwNzNjMTI4MzEvdGFibGVyYW5nZTozNGQwYTZlMTBhNDA0OTk5YWUwYWEwNDA3M2MxMjgzMV8yLTEtMS0xLTE2MjQyNg_38becb61-cdb2-4195-be7a-067332bbaaba">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ilmn-20230109.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001110803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-09</xbrli:startDate><xbrli:endDate>2023-01-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="idd34d28522d445078041d2fa117c4005_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml84Mg_aaab4603-f37b-4996-aeaf-de7e628bf4ad">8-K</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Current Report</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8yMjI_2d948ad3-ea7f-4f71-98f9-80e1ea933f2a">January&#160;9, 2023</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><img src="ilmn-20230109_g1.jpg" alt="ilmn-20230109_g1.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8yMjg_cde71004-901d-42f6-9179-1e3e46033aeb">Illumina, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8yODc_0c2e294b-72a1-4990-90e6-ae8b121b9928">001-35406</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Commission File Number)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGFibGU6ZjVkMDc4ZWEwNmI5NDhkNTg2M2ZmM2I2YmJkZmE4ZTAvdGFibGVyYW5nZTpmNWQwNzhlYTA2Yjk0OGQ1ODYzZmYzYjZiYmRmYThlMF8wLTAtMS0xLTE2MjQyNg_fb918ec4-6333-4041-8e0a-dc3fbb24baab">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGFibGU6ZjVkMDc4ZWEwNmI5NDhkNTg2M2ZmM2I2YmJkZmE4ZTAvdGFibGVyYW5nZTpmNWQwNzhlYTA2Yjk0OGQ1ODYzZmYzYjZiYmRmYThlMF8wLTItMS0xLTE2MjQyNg_5e0f000e-5591-49f1-98c3-cffc3710508b">33-0804655</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8zMTc_d360f3db-a32f-4099-a2a9-b2c32f0e2b56">5200 Illumina Way</ix:nonNumeric>, <ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8zMjE_163cab63-3522-4200-9767-cd0df520e512">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8zMjU_0f754a16-2570-4f54-a81f-46292df5d99b">CA</ix:nonNumeric> <ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8zMjg_0596d85c-e604-4f47-8067-e62f04eddd65">92122</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8zODU_650e3e8c-86df-4e78-9e9a-b667fa34d8b4">858</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8zODk_eb41857f-c372-45e6-97fa-a2db01e02b14">202-4500</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8xNjc4_a22ba31b-65bf-4d00-9cd1-a29b7f6e6c56"><ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml82ODU_90ede0c5-81d8-474a-8a1e-c53bcbabda4d">&#9744;</ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8xNjc5_a1cc79eb-be1c-425f-b340-33b39c7f87fe"><ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml83Nzg_23946e7c-24f1-4f44-bb76-87f7f149fbd6">&#9744;</ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml84NzI_d5a5408c-71fa-405c-a155-86c78759056e">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml85ODI_b7eaa39f-ebfb-4cfa-8baa-3e3a6c14af90">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGFibGU6MmI0YjE3ZDIyZjE4NGM1YWEwYmJhNTJmMmI4OTA1NGQvdGFibGVyYW5nZToyYjRiMTdkMjJmMTg0YzVhYTBiYmE1MmYyYjg5MDU0ZF8xLTAtMS0xLTE2MjQyNg_5ce7d720-0041-4f6b-ad35-d9d3d7d3d7dc">Common Stock, $0.01&#160;par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGFibGU6MmI0YjE3ZDIyZjE4NGM1YWEwYmJhNTJmMmI4OTA1NGQvdGFibGVyYW5nZToyYjRiMTdkMjJmMTg0YzVhYTBiYmE1MmYyYjg5MDU0ZF8xLTEtMS0xLTE2MjQyNg_6993fd33-ea8d-4d66-93ef-76a26a98cc64">ILMN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGFibGU6MmI0YjE3ZDIyZjE4NGM1YWEwYmJhNTJmMmI4OTA1NGQvdGFibGVyYW5nZToyYjRiMTdkMjJmMTg0YzVhYTBiYmE1MmYyYjg5MDU0ZF8xLTItMS0xLTE2MjQyNg_ffe3a804-0a9e-4b47-bae9-8e11dcbde1ea">The NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  <ix:nonNumeric contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8xNDE3_397b8f98-fe9d-47b3-9929-0fb2732161b8">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idd34d28522d445078041d2fa117c4005_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">TABLE OF CONTENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd34d28522d445078041d2fa117c4005_10">Item 2.02 Results of Operations and Financial Condition</a></span></div><div style="text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd34d28522d445078041d2fa117c4005_13">Item 9.01 Financial Statements and Exhibits</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd34d28522d445078041d2fa117c4005_16">SIGNATURES</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd34d28522d445078041d2fa117c4005_19">Exhibit Index</a></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idd34d28522d445078041d2fa117c4005_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#idd34d28522d445078041d2fa117c4005_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02 Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2023, Illumina, Inc. (the "Company"), presented at the J.P. Morgan Healthcare Conference in San Francisco, California during which it discussed preliminary financial results for the fourth quarter and fiscal year ended January&#160;1, 2023. The presentation was webcast on the Company&#8217;s website, and it will remain available in the Investor Relations section of the Company&#8217;s website for at least 30 days following. Pursuant to General Instruction F to Form 8-K, a copy of the transcript from the presentation (the "Transcript") is attached hereto as </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex991transcriptjpm2023.htm">Exhibit 99.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and is incorporated into this Item 2.02 by this reference.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information furnished pursuant to this Item 2.02 shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idd34d28522d445078041d2fa117c4005_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#idd34d28522d445078041d2fa117c4005_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01 Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div style="text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;Exhibits.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex991transcriptjpm2023.htm">99.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Transcript of Illumina, Inc. presentation at the J.P. Morgan Healthcare Conference on January 9, 2023</span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex992reconofprelimnon-gaap.htm">99.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Reconciliation of preliminary non-GAAP results of operations for the fiscal year ended January&#160;1, 2023</span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex993reconofnon-gaapguidan.htm">99.3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Reconciliation of non-GAAP financial guidance for fiscal year 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104&#160;&#160;&#160;&#160;Cover Page Interactive Data File (embedded within the Inline XBRL document)&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idd34d28522d445078041d2fa117c4005_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#idd34d28522d445078041d2fa117c4005_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ILLUMINA, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January&#160;10, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:&#160;&#160;</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OYDEEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OSWAMI</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joydeep Goswami</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Strategy and Corporate Development Officer and Interim Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idd34d28522d445078041d2fa117c4005_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#idd34d28522d445078041d2fa117c4005_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;Index</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex991transcriptjpm2023.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcript of Illumina, Inc. presentation at the J.P. Morgan Healthcare Conference on January 9, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex992reconofprelimnon-gaap.htm">99.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of preliminary non-GAAP results of operations for the year ended January&#160;1, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex993reconofnon-gaapguidan.htm">99.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of non-GAAP financial guidance for fiscal year 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991transcriptjpm2023.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i08ee706f20f4486eac0cc95e79d8b9d8_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">CORPORATE PARTICIPANTS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Francis A. deSouza&#59; Illumina,Inc. - CEO &#38; Director</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Joydeep Goswami&#59; Illumina, Inc.- Chief Strategy &#38; Corporate Development Officer and Interim CFO</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">CONFERENCE CALL PARTICIPANTS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Ruizhi Qin&#59; JPMorgan Chase &#38; Co, Research Division - Analyst</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">PRESENTATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Ruizhi Qin</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">All right. Good afternoon, everyone. Welcome to our next company presentation by Illumina. I'm Julia Qin, life science tools and diagnostics analyst at JPMorgan. And let me turn the stage over to Francis. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Francis A. deSouza</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Thanks, Julia, and the JPMorgan team for hosting us, and thank all of you for joining us today. I'm Francis deSouza, the CEO of Illumina. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">As a reminder, our presentation today includes forward-looking statements, non-GAAP measures and reconciliations to GAAP measures. Please refer to our SEC filings for a presentation of risks. Also, please review our statements on the hold separate requirement related to GRAIL. GRAIL must be held and operated separately and independently from Illumina pursuant to the interim measures ordered by the European Commission, which prohibited our acquisition of GRAIL. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Today, I'll cover 3 areas in our presentation&#58; first, a company overview, including preliminary 2022 results and 2023 guidance. Second, I'll review our sequencing platforms business and NovaSeq X. And third, I'll cover how we're accelerating clinical genomics, including an update on GRAIL. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">I'll start with who we are. Our mission at Illumina is to improve human health by unlocking the power of the genome. Illumina sequencers enable researchers and clinicians to accurately read genomes, decode how they translate into health and disease and to leverage those insights in patient care. Our vision is that genomics will transform lifetime health management. Billions of people will have our genome sequenced many times over our lifetimes to prevent and optimally treat, improving outcomes and lowering costs as we fight disease. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Carrier screening and noninvasive prenatal testing will be standard. Newborns will be sequenced as a frontline diagnostic for suspected genetic conditions. Genomic testing will be routine for early detection of diseases, including cancer and neurodegenerative diseases. And therapy effectiveness and recurrence monitoring will be required at every progressive treatment line. Illumina touches every step. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">To make this vision a reality, we are working to enable more discoveries and to make genomics a standard part of clinical care. By 2027, our addressable market will be $120 billion, a sixfold increase from 2014 as clinical oncology, genetic disease and reproductive health testing expand and new research modalities like multiomics, single cell and spatial emerge. Our market today is only 7% penetrated, going to 14% by 2027, driven by increased adoption of genomics globally. Illumina is at the center of this rapidly growing genomics landscape. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">We have unmatched scale, differentiation and diversification. We serve over 9,500 customers across 155 countries with an installed base of approximately 23,000 instruments. In 2022, we delivered over $4.5 billion in revenue, with more than 80% of our revenue coming from recurring sources, including consumables and services. We achieved this through our relentless focus on innovation. We have over 8,800 patents worldwide and invested $1 billion in R&#38;D in 2022. This positions us very well to deliver on our long-term targets of mid-teens revenue growth and high teens operating profit growth. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Turning now to our financial results. Illumina delivered consolidated revenue of $1.075 billion for the fourth quarter 2022 with core revenue of $1.058 billion, GRAIL revenue of $23 million and with record NextSeq shipments. Full year consolidated 2022 revenue was $4.576 billion, and consolidated non-GAAP operating margin was 10.4%. Core Illumina revenue was $4.545 billion, non-GAAP gross margin was 69%, and non-GAAP operating margin was 23.5%. GRAIL revenue was $55 million for the year. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Turning to performance by platform. We placed more than 3,200 instruments in 2022, bringing our installed base to approximately 23,000 instruments. We shipped 340 NovaSeq 6000s in 2022 and had $1 million in average pull-through per instrument. We had strong placements in the first half of 2022 even after a record 2021. Second half placements were tempered by growing customer excitement for NovaSeq X. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">We shipped a record 1,210 mid-throughput instruments and saw the fourth consecutive record year for NextSeq shipments. For low throughput, we saw 1,670 shipments with 500 new customers. And in 2022, we delivered multiple innovations that will lead to the next waves of growth for Illumina and for genomics. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Turning now to 2023. We expect 2023 revenue growth of 7% to 10%, with Core Illumina revenue growth of 6% to 9% and GRAIL revenue growing at approximately 80%. This is driven by multiple factors&#58; the NovaSeq X upgrade cycle, momentum in mid-throughput following a record 2022, consumables growth from our expanding installed base, demand elasticity and accelerating adoption of the Galleri test. Non-GAAP operating margin for Core Illumina of approximately 22% is consistent with higher instrument shipments in a launch year, margin improvements beyond 2023 as the NovaSeq X installed base comes online and consumables ramp. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">We expect an operating loss for GRAIL of approximately $670 million, reflecting investments to support an FDA application, NHS trial and expanding the commercial </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">organization. GRAIL is making progress on its path to profitability and will approach breakeven in the next 5 years. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Illumina's strategy involves innovating in both, leading the industry in sequencing platforms and accelerating clinical genomics globally, starting with our leadership in sequencing platforms. High-throughput represents the largest part of our portfolio by revenue. This quarter, we will begin shipping the revolutionary NovaSeq X series, the most powerful, most sustainable and most cost-effective sequencer ever developed. NovaSeq X can sequence 20,000 genomes per year, 2.5x higher throughput and 2x faster than the NovaSeq 6000. This speed enables single-day runs with turnaround time under 24 hours. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">NovaSeq X is also the world's most sustainable high-throughput sequencer with a 61% reduction in climate change impact. It's the only high-throughput sequencer to eliminate the need for dry ice for shipping, expanding the market and improving efficiency. NovaSeq X is also the most cost-effective high-throughput sequencer, delivering the most accurate genome, short- and long-reads multiomic analysis in a single flow cell on a single run on 1 instrument. And NovaSeq X is the only high-throughput sequencer with onboard analysis, variant calling and up to 5x lossless data compression. Savings from the built-in DRAGEN analysis on board over 5 years can cover the cost of the NovaSeq X. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">These features collectively provide fast, easy, more complete and fully analyzed genomes at a cost as low as $200 per genome with analysis. NovaSeq X has over 40 patent applications, took 5 years and 1,500 scientists, engineers, developers and designers to create. These innovations make high efficiency, high-throughput sequencing accessible at a global scale. Customer response has been fantastic, exceeding our expectations, and we already have over 140 orders for NovaSeq X Plus and an advanced pipeline of more than 200 orders. We plan to ship 40 to 50 instruments in Q1 and over 300 instruments in 2023. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The strong global interest with orders for more than 25 countries, 4x more than in the first quarter after the NovaSeq 6000 launch. We're also seeing stronger-than-expected demand from the clinical customers, with more than 35% of orders coming from the clinical segment who are bringing on higher-intensity sequencing applications such as liquid biopsy, MRD and other multiomic tests. And approximately 15% of orders are from new to high-throughput customers who are bringing sequencing in-house due to NovaSeq X's ease of use and cost benefits. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This represents the strongest pre-order book we've seen with any Illumina instrument launch. And this demand will catalyze a multiyear upgrade cycle. Over the next few years, we expect average pull-through for NovaSeq X to comfortably exceed NovaSeq 6000's as NovaSeq X unlocks the market's demand elasticity, enabling more samples, more analysis per sample and more sequencing intensity per analysis. I'll walk through each. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">There are 3 major factors contributing to the growth of samples. First, genomics combined with clinical information can increase drug discovery success by up to 150% </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">and reduce costs by up to 50%. To achieve this, we need more samples over time and from a more diverse population. For example, the All of Us initiative aims to partner with at least 1 million Americans to accelerate medical breakthroughs, and 80% of participants represent historically underrepresented communities in medical research. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The need for genetic diversity in databases is also driving these larger cohorts. Today, we announced that Amgen and its subsidiary, deCODE Genetics, will sequence the first 35,000 genomes in our collaboration with Nashville Biosciences, representing the largest set of black individuals sequenced to date. And the Singapore PRECISE 100,000 Genome Project is creating the largest and most complete Southeast Asian genomic data set. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Second, new areas in oncology include a broader group of patients and more testing per patient. MRD testing is done multiple times for those undergoing cancer treatment and those in remission. In early detection, anyone over the age of 45 with a family history of cancer or other risk factors will be tested regularly throughout their lifetime. Together, these expand the population tested on a repeated basis by 100 times. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Third, techniques such as single cell and spatial analysis are creating multiple samples from what used to be a single sample. NGS forms the basis of deeper molecular analyses of these samples. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Turning now to the second driver of elasticity. Researchers and clinicians are additionally running additional omics analysis on a single sample for a more comprehensive molecular understanding. NGS is enabling these analyses at scale as it did with DNA, and the cost and workflow of NovaSeq X will accelerate this trend. For instance, researchers are increasingly conducting whole transcriptome analysis at scale to get complete mRNA information in addition to DNA. Also, NGS is, for the first time, enabling scaled proteomics research with simultaneous analysis of thousands of proteins from hundreds of samples. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">NovaSeq X reduces the cost and data analysis barrier and with multiple flow cell lanes, provides flexibility to do multiple analyses at the same time on the same run. These capabilities enable new studies to include genomics and proteomics where genomics may have been the only thing considered previously. For example, the U.K. biobank recently partnered with Olink for proteomic analysis of 50,000 of their 500,000 biobank samples. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Third, customers are increasing the intensity of sequencing for each analysis, looking for more sensitivity, specificity and information from each sample. We're seeing this in cancer testing as customers move from small panels to comprehensive genomic analysis, increasing the output per sample by a factor of 5. And the expansion of liquid biopsies due to lack of available tumor tissue, the reduced cost and better patient compliance translates to 12 to 15x more sequencing than solid tumor testing. We're seeing this growth already across customers engaged in liquid biopsy testing. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Lastly, as costs for sequencing and bioinformatic analysis decrease and workflows improve, there is a trend towards whole genomes rather than panels, increasing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">sequencing intensity by 40 times. Many customers, including CeGaT in Germany, will use the cost and efficiency benefits of NovaSeq X to accelerate this trend. NovaSeq X's higher output per analysis enables customers to rethink analysis for their projects in ways that they weren't even considering before. Multiple customers have said that the NovaSeq X enables them to start with genomes in projects that were previously exome-focused. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Now turning to mid-throughput. We had a fourth consecutive year of record NextSeq shipments with NextSeq 1000&#47;2000 consumable revenue doubling from 2021. We expect further NextSeq 1000&#47;2000 expansion in 2023 across applications, including multiomics, genetic disease research and cancer research. Customers appreciate NextSeq 1000&#47;2000's unique capabilities as the only mid-throughput sequencer with built-in analysis and the first mid-throughput instrument to include the 2 x 300 longer read kits. In early 2024, we will make the new XLEAP-SBS chemistry available on existing NextSeq 1000&#47;2000 instruments. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Now to low throughput. Low throughput is a great way to enter into sequencing and then later enable upgrades to mid- and high-throughput sequencers as projects expand. And Illumina's low-throughput instruments have been used in over 130,000 publications, more than all other sequencing companies combined. Our low-throughput instruments attract hundreds of new customers each year, opening up new geographies and applications like infectious disease. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">I'll now touch on Illumina complete long reads. Illumina complete long reads is the only offering that addresses the 5% of hard-to-reach genic regions at scale with high accuracy, all on a single instrument and with 90% less DNA input than other long reads. This year, we will launch 2 products, a whole genome assay and an enrichment panel, enabling a comprehensive high accuracy, long-read view for as little as $600 per genome. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Turning now from our products to accelerating clinical genomics. Over the last decade, Illumina has built a clinical infrastructure with deep expertise, scale and reach. Clinical consumable shipments were $1.3 billion in FY 2022 revenue, representing 45% of our total sequencing consumables. We serve more than 5,000 clinical customers with 10 IVD EUA product families and 1,200 product registrations and regulatory approvals of over 62 countries. Our instruments, reagents and software are core components of many of our clinical customers' workflows and processes. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Oncology represents a $78 billion market for sequencing. In the next 5 years, we expect NGS penetration of this market to grow at a 30% CAGR. Multiple trends are driving this growth. Tumor-naive approaches will be used in pan-cancer targeted therapies requiring deeper sequencing and more liquid biopsy. Pharma drug development will drive dollars towards applications, including vaccines and targeted therapies, and patients will have multiple tests over their lifetimes. We see significant need across the cancer journey, starting with early detection. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The GRAIL Galleri blood test is the only commercially available multi-cancer early detection test, addressing a $44 billion early screening market. Galleri's blood test </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">screens for more than 50 cancer types, 45 of which do not have another recommended screening test. And it's the only test which pinpoints cancer location with 89% signal of origin accuracy. With its breadth and precision, GRAIL is predicted to avert 1 in 3 cancer deaths over a 5-year time frame. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">In addition to Galleri, GRAIL is working on a unique multi-cancer MRD test that doesn't require a tissue biopsy and enables a 2 to 3x reduction in turnaround time relative to customized approaches that require tissue biopsies. Illumina reacquired GRAIL in 2021, and as we work through the regulatory process, we're also exploring strategic options related to the divestiture order from the European Commission expected this quarter. We'll keep you updated. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">GRAIL had a very strong 2022. Consumer demand for the Galleri test has exceeded expectations with physician orders for more than 60,000 tests received to date. Galleri had the fastest first year revenue ramp in cancer screening test history. GRAIL has established over 60 partnerships with leading health systems, self-insured employers and other health care stakeholders. In 2022, more than 4,500 providers ordered the test. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Galleri received FDA Breakthrough Designation, was recognized by Time as one of the best inventions of 2022, The Atlantic is one of the breakthroughs of the Year and Fast Company as one of the world-changing ideas of 2022. Clinical trial data for Galleri is consistent and positive, and real-world evidence of more than 38,000 patients corroborates this data. Provided reported cancers detected with Galleri include stage 1 pancreatic, head and neck, endometrial, esophageal and gastrointestinal stromal tumor cancers&#59; and stage 2 rectal, liver and head and neck cancers. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Galleri has also had a very positive reaction from consumers with a 97.1% satisfaction rate. GRAIL is making progress towards reimbursement with 300,000 participants across multiple studies and a final FDA submission expected in 2024, 2025. GRAIL's NHS trial spans 140,000 participants with a rollout of up to 1 million people beginning in 2024 if the trial is successful. This exciting momentum translates into an expected GRAIL revenue CAGR of 60% to 90% over the next 5 years. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Turning now to therapy selection. Illumina participates in the $9 billion therapy selection market by providing sequencing systems to more than 1,100 therapy selection test developers who performed approximately 1.75 million tests in 2022 alone. In addition, we provide our leading 2-site oncology offerings or TSO 500 to 1,500 oncology testing service providers. In 2022, TSO 500 sample volume grew 60% year-over-year across more than 500 customers, and we expect more than $100 million in 2023 revenue. Also, in 2023, we expect TSO's IVD registration in Europe and to submit for IVD registration in the U.S. and Japan. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Moving to Minimal Residual Disease monitoring or MRD. MRD is a $25 billion market that's only 1% penetrated. Early traction is strong with more than 200,000 tests performed in 2022, up 140% year-over-year. Illumina is well positioned with more than 10 MRD solutions in development on Illumina platforms. And payers are recognizing the therapeutic impact of MRD. In the U.S., 4 indications are currently covered by Medicare </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">and 2 by commercial players, with an additional 8 indications expecting coverage by 2025. We look forward to seeing this market and the rest of our clinical applications grow in 2023 and beyond. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">In closing, Illumina has a best-in-market portfolio, global infrastructure and team serving large, expansive growing markets. In 2023, we're looking for the NovaSeq upgrade cycle -- the NovaSeq X upgrade cycle and momentum in mid-throughput following a record 2022. We also expect to see consumables growth from our expanding installed base, unlocking of demand elasticity and accelerating adoption of the Galleri test. All of these move us closer to our mission of improving human health by unlocking the power of the genome. We look forward to sharing more with you in the coming months, including on our earnings call on February 7. Thank you. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">QUESTIONS AND ANSWERS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Ruizhi Qin</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Thank you, Francis, for the great overview. Please welcome the rest of the management team on stage for Q&#38;A. (Operator Instructions) </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">So I can get us started, maybe starting with the '23 outlook. Last quarter, you talked about your preliminary view of 10% reported growth. You're guiding to 7% to 10% reported and 6% to 9% Core Illumina. So maybe just talk about what has changed about your view since then&#63; And what are you assuming at the lower and upper end of your guidance&#63; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Francis A. deSouza</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Yes. We're looking for 2023 to be an exciting year for us on a number of perspectives. So what we said earlier was we're expecting revenue growth closer to that 10%. And what's going to drive this year is going to be the few things I talked about. One, obviously, we're entering a big upgrade year, right&#63; And so we're launching the X in Q1. And we're kicking off, it's probably one of the biggest upgrade cycles in sequencing, right, as we upgrade our high-throughput customer base. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">And so one of the things to watch over the course of the year will be, obviously, how that upgrade cycle is going. We feel really good about the preorders that have come in to date. And with the numbers we have already, we're effectively sold out not just for Q1 but for most of Q2, too. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">And so we feel really good about the demand side of it. And obviously, the work to do now is to scale up manufacturing. We're looking to ship 40 to 50 units in Q1, 300 units of the year -- over the year. So one of the things to watch will be that ramp. And I think that represents, certainly from a demand side, upside potential for us. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The other thing we're going to be watching for this year is how the X unlocks some large projects driven by the demand elasticity that X will tap into. And so while we haven't built that into our guide for the year, we're talking to customers about projects that they would </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">like to kick off. And so we're going to be watching the timing of those projects and what of those projects come in this year versus in the coming years as we roll out the X. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">And on the other side of the ledger, we're continuing to monitor the macroeconomic environment, the situation in China, inflation and so on. And so that's sort of the puts and takes as we look at the rest of the year. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Ruizhi Qin</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Got it. So it's fair to interpret that it's more prudent approach to your '23 outlook. Obviously, the NovaSeq X order book is really strong and should support a lot of upside like you mentioned. Have there been any changes or evolution in any of the near-term headwinds that you previously talked about, like consumable destocking, like customer lab expansion delays and things like that&#63; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Francis A. deSouza</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Yes. I think we are -- as we sort of lapped the second quarter of last year, we first started to see some of the destocking. That's certainly going to be less of a factor into 2023. And then in terms of lab expansions, some of the customers that have delayed it have got those back on track. But from a guide perspective, we're not really assuming any big lab expansions will play out in 2023. And so really, the story of this year is going to be some of the things I talked about earlier, the upgrade cycle and those much more than some of those other things. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Ruizhi Qin</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Awesome. So speaking of the NovaSeq order book, 140 orders, a very strong number. How does that compare to your internal expectations&#63; And in terms of the customer mix, 35% commercial, is that in line with your expectations&#63; Or how should we think about the continued momentum going forward&#63; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Francis A. deSouza</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Yes. We've been working on this product for 5 years, right&#63; And so we had many, many people -- and we had incredibly high expectations for its launch, as you can imagine. And NovaSeq X has exceeded all of them, right&#63; We are -- the order book we have right now has exceeded what we -- where we expected to be for this time in the launch. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">And there have been a number of places where we've been surprised. One is we're surprised by the clinical interest. What we had modeled coming in is what we saw with the 6000, which is the first set of customers that would deploy the X we expected would be in academic and research environments. And they'd be the first ones that would be replatforming their fleets to take advantage of the benefits of the X. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">And that's certainly happening, but what we've also seen our clinical customers come onboard. And we said that 35% of the preorders we've got have come from clinical </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">segments, and we didn't expect it to be as big as it was. And so that's been a nice upside surprise. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">We've also seen more new to high-throughput customers come into the preorder book than we expected. This is -- it's a very powerful machine. We didn't -- we weren't expecting as many people to use this as their entry point into new to high throughput. But what's played out is that the operational ease of use that we delivered with X has made that power accessible to customers that, frankly, were a little intimidated to bring sequencing in-house before. And so it's the economics as well as the streamlined workflows, the operational efficiencies, the built-in analysis, which is a big deal in terms of reducing the bioinformatics hurdle to deploying sequences. And so that surprised us to see 15% of the order base come in from new to high throughput. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">We're also surprised by the global demand. We've talked about the fact this is several times more interest in preorders from countries around the world than we saw even with the 6000. And part of it is driven by the operational efficiencies and ease of use that are built into the X. But part of it is also driven by the investments we made around eliminating the need for a cold chain and dry ice and shipments. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">And so now you have these instruments that are accessible to parts of the world that may have a cold chain but don't have a reliable cold chain. And so now they feel they can comfortably bring in sequencing in-house rather than sending samples outside the country. And so we didn't expect again quite the global interest that we've seen. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Ruizhi Qin</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Awesome. In terms of just how to think about the continued momentum of that order trajectory, what do you think is the magnitude of year-end budget flush benefit that you saw in 4Q, and how to think about the order book going from here&#63; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Francis A. deSouza</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Yes, I think there's no question now that demand is going to vastly exceed what we can supply this year. I think we're so far -- it's so clear now that this year, we're going to be supply limited. The 300, we could comfortably raise that a lot because the demand is broad. I mean ultimately, we do believe that not only will you see every customer that's got a NovaSeq 6000 ultimately upgrade to the X. Again, it's so far better in terms of performance and anything out there. But we'll also see, again, a significant expansion of the market. The demand elasticity that NovaSeq allows customers to tap into is a very significant factor. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">It's why -- I'll give you an example. Part of the interest we saw from clinical customers are customers that are doing liquid biopsy applications. And we talked about the fact that liquid biopsy requires a lot more sequencing than if you were using solid tumor tissue, right&#63; And so those are the kind of applications that I think the X will dramatically expand, and I talked a little bit about that in my presentation. And so I think we will see a multiyear both upgrade cycle as well as new customers coming into the X. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Joydeep Goswami</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">You're also kind of seeing that with the increased clinical interest so early, right&#63; That's exactly moving to a higher throughput, more kind of specificity, more sensitivity being required in these assets. So you're already starting to see that very, very early in the cycle. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Ruizhi Qin</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Right. Obviously, you're working on ramping up your manufacturing capacity to catch up with that strong demand. What's the run rate capacity that you're hoping to reach by year-end, 500 systems a year, more&#63; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Francis A. deSouza</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Well, I mean if you sort of run the math right, in terms of -- we're going to start with 40 to 50 in Q1. We're going to ship over 300 for the year. So even the math tells you, we're going to be comfortably above even 80 instruments per quarter. And the reality is we have a fantastic operations team that as demand comes in, we can scale that up if we need to. And so the hard part of the work and it's all a hard part, but it's the scaling up that's happening now to make sure that we've sort of fixed a reproducible manufacturing process that we've scaled up, all the vendors that we need, all the suppliers that we need. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">And so a big part of the work is really just this year. And then once we get to Q4, we feel that it's easier for us to then scale up as demand continues to grow. But we expect this year, we're going to exit with being able to make over 80 instruments per quarter and then building up from there. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Ruizhi Qin</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Got it. And that capacity constraint is only on the instrument side or is it on the consumable side as well&#63; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Francis A. deSouza It's a little bit -- both of them are going to be new processes, right&#63; So as I said with the X, we have redesigned that instrument from the ground up. Every part of X is new. So if you look on the consumable side, if you look at the chemistry, the entire chemistry is new. It's new FFNs, it's new reagents, it's new dyes, it's new blocker, it's a new everything. What that means is every part of the manufacturing process is new. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">On the flow cell, we have a new mill process for manufacturing our flow cells, that's new as well. And so every part of our manufacturing is being scaled up and started being scaled up in the middle last year, right&#63; And so we're working through that, and we'll scale all of it up over the course of the year. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Ruizhi Qin</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Got you. Now turning to NovaSeq 6000. Can you talk about the residual demand you saw in 4Q and what's your expectation&#63; Did you maybe take a slightly lower as well in your updated '23 outlook&#63; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Francis A. deSouza</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Yes. I think 2 things are very clear. One, that going forward, the biggest part of both the demand and then the shipments will be on the X, right&#63; At some point, as we ship the X, that will be the primary instrument that our customers will want and that will be, therefore, the primary instrument that we'll ship and that's what will drive our revenue. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Having said that, it's also true that there are customers that are using the 6000 in production at scale. And if you are a research customer that's in the middle of running a large cohort for a project, you're going to continue to do that on the 6000 most likely. And that will continue to drive some demand for the 6000s, both on the instrument side as well as the consumables side. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Similarly, our large clinical customers have validated workflows that they've built on the 6000. And as those applications continue to scale, they will continue to drive demand for 6000s, again, both on the instrument side as well as the consumables side. So you will continue to see us ship 6000s, both hardware and consumables going forward, but certainly the biggest part of the revenue for us going forward in high-throughput is going to be on the X. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Ruizhi Qin</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Got you. Speaking of the competitive landscape in the high-throughput market, BGI is allowed to enter the U.S. market this year. How meaningful a competitive threat do you view them&#63; Or do you think them as a bigger playing OUS markets rather than the U.S. market&#63; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Francis A. deSouza</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">We've always had competition, frankly. Even when we entered the sequencing market in 2007, there were players in the market, and we always take competition seriously. And so we continue to monitor the market. And we want to make sure that from a customer perspective, we're continuing to provide the best value proposition to our customers across the dimensions that they care about. Performance is certainly one, cost effectiveness and ease of use, the clinical infrastructure that we deliver. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">And so we're going to continue to take competition seriously and monitor the market. But our focus will continue to be obsessively focused on our customers and what they want. And fortunately, and Susan Tousi, our Chief Commercial Officer, is here in the audience, but fortunately, we have a fantastic commercial organization that is very close to our customers. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">And so I said we have over 9,500 customers in 155 countries. And so we have a sort of a front-row seat to what our customers not only want today but will want in the future. And so that informs our thinking around how we invest for our road map. And so frankly, the biggest part of our attention is always going to be on what our customers are thinking about, what they wish they could do in the future, and that's going to drive our innovations. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">And that's why in a lot of cases, you see us do things that frankly nobody else did, for example, the elimination of need of dry ice, right&#63; We're the only company that made those investments to remove the need for a cold chain in your supply. And that was because our customers told us that, that was very onerous for them, that unlock -- the unpacking the reagents was a big operational disruption. And frankly, they wanted big science to be green science. And so that's what led to our investments in those sustainability features, for example, not because there's anybody else doing it, nobody else is. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Ruizhi Qin</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Got you. Just sticking with the core business for a minute. Can you talk about the gross margin and operating margin trends in 4Q&#63; And you're obviously assuming some deterioration in '23. So just help us think through the puts and takes and drivers there. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Francis A. deSouza</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Sure. Maybe I'll turn it over to you, Joydeep. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Joydeep Goswami</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Yes. Julia, sorry, was that Q4 or 2023&#63; Which&#63; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Ruizhi Qin</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">For both, please. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Joydeep Goswami</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">For both. Yes, I think Q4 margins came in close to where we were expected, maybe slightly higher as we continue to drive efficiencies through the process. But 2023, we had said that gross margins would be towards the lower end of the range, high 60s to low 70s that we have provided. The reason for that is quite simple, right&#63; It's the first year of a major instrument launch. We expect the mix to be skewed more towards instruments and therefore, lower margins. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Now of course, as we move forward, we do expect that, as Francis mentioned, right, demand elasticity will pick up. You'll have more of the consumables, and we expect to see gross margins improve as we go into 2024 and beyond. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Ruizhi Qin</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">We're almost out of time, but I want to squeeze in 1 more obviously. We know -- I know you're still waiting for the EC divestiture order, but what's your interpretation of the word that GRAIL should be restored its independence swiftly&#63; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Francis A. deSouza</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Yes. So the European Commission has emphasized a few things, I think Swift is one. So I think we're all incentives sort of move as quickly as possible through this process, the European Commission and Illumina both. The other thing they've emphasized is they want to make sure that we're doing the right thing for GRAIL and GRAIL's customers. So they recognize the life-saving potential of the GRAIL Galleri blood test. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">And what they're saying is, look, whatever we do has to make sure that we protect GRAIL's ability to be successful in the future and bring the potential life-saving benefits of that test to customers around the world. So that's another true north, if you like, both for the European Commission and for us. And so they're saying, look, what we're balancing here is we want to move quickly but we also want to make sure we're doing the right thing to make sure that GRAIL Galleri and its customers are set up for success and able to bring its life-saving test to customers around the world in a responsible way. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">And obviously, from our perspective too, the other part of the true north is to make sure that we're doing the right thing for Illumina shareholders, right&#63; And so those are the 3 things that are probably driving our thinking. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Ruizhi Qin </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Great. Well, let's wrap it up there. Thank you so much for everyone for your time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex992reconofprelimnon-gaap.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i76f1dfad94824b2799600dbd034e095a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Illumina, Inc.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preliminary Results of Operations - Non-GAAP</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</font></div><div style="margin-top:3pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance and financial results are subject to risks and uncertainties, and actual results could differ materially from the preliminary results set forth below. Some of the factors that could affect our financial results are included from time to time in the public reports filed with the Securities and Exchange Commission, including </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1110803/000111080322000013/ilmn-20220102.htm" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-K</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fiscal year ended January 2, 2022 filed with the SEC on February 18, 2022, </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1110803/000111080322000021/ilmn-20220403.htm" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-Q</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fiscal quarter ended April 3, 2022, </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1110803/000111080322000041/ilmn-20220703.htm" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-Q</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fiscal quarter ended July 3, 2022, and </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1110803/000111080322000047/ilmn-20221002.htm" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-Q</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fiscal quarter ended October 2, 2022. We assume no obligation to update any forward-looking statements or information.</font></div><div style="margin-top:13pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The preliminary unaudited information included in the tables below is approximate and subject to change. We will report our fourth quarter and full year fiscal 2022 results in February.</font></div><div style="margin-top:13pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED RECONCILIATION BETWEEN PRELIMINARY GAAP AND NON-GAAP OPERATING MARGIN&#58;</font></div><div style="margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:77.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year 2022</font></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preliminary GAAP operating margin</font></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(91.2)%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</font></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related expenses </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(b)</font></div></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(c)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.5</font></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(d)</font></div></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(e)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</font></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal contingency and settlement </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(f)</font></div></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preliminary non-GAAP operating margin </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)</font></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4%</font></td></tr></table></div><div style="margin-top:13pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CORE ILLUMINA RECONCILIATION BETWEEN PRELIMINARY GAAP AND NON-GAAP OPERATING MARGIN&#58;</font></div><div style="margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.830%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth Quarter 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year 2022</font></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preliminary GAAP operating margin - Core Illumina</font></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.8%</font></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.6%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</font></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related expenses </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(b)</font></div></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</font></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(d)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7</font></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(e)</font></div></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</font></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal contingency and settlement </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(f)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3</font></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preliminary non-GAAP operating margin - Core Illumina </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)</font></div></td><td colspan="3" style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7%</font></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5%</font></td></tr></table></div><div style="margin-top:13pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CORE ILLUMINA RECONCILIATION BETWEEN PRELIMINARY GAAP AND NON-GAAP GROSS MARGIN&#58;</font></div><div style="margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:77.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year 2022</font></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preliminary GAAP gross margin - Core Illumina</font></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">68%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preliminary non-GAAP gross margin - Core Illumina </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)</font></div></td><td colspan="3" style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69%</font></td></tr></table></div><div style="margin-top:13pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-GAAP gross profit, included within non-GAAP operating profit, is a key measure of the effectiveness and efficiency of manufacturing processes, product mix and the average selling prices of our products and services. Non-GAAP gross margin and non-GAAP operating margin exclude the effects of the pro forma adjustments as detailed above. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing past and future operating performance, including in the non-GAAP measures related to our Core Illumina segment.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amounts consist primarily of legal expenses related to our acquisitions.<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Amount consists of goodwill impairment recorded in Q3 2022 related to our GRAIL reporting unit.<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Amounts consist primarily of employee severance costs and a lease impairment charge</font><font style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">related to the restructuring event that occurred in Q4 2022.<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(e) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amounts consist primarily of fair value adjustments for our contingent consideration liability related to the GRAIL acquisition.<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Amounts consist of litigation contingency and settlement expense of $145 million related to the settlement of our litigation with BGI and an accrual of $458 million for the potential fine that the European Commission may impose on us of up to 10% of our consolidated annual revenues.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSOLIDATED RECONCILIATION BETWEEN PRELIMINARY GAAP AND NON-GAAP TAX RATE&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:66.516%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.342%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year 2022</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current (b)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">If repealed (c)</font></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preliminary GAAP tax rate</font></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</font></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP tax adjustments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> (a)</font></div></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preliminary non-GAAP tax rate</font></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-top:13pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-GAAP tax adjustments reflect the tax impact related to preliminary non-GAAP adjustments, the impact of GRAIL pre-acquisition net operating losses on GILTI and the utilization of U.S. foreign tax credits, and </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the difference between book and tax accounting related to stock-based compensation cost.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts assume that the existing R&#38;D capitalization requirements are not repealed retroactive to 2022 and, as a result, reflect an impact of approximately $100 million.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <br>(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts assume that the existing R&#38;D capitalization requirements are repealed retroactive to 2022.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>ex993reconofnon-gaapguidan.htm
<DESCRIPTION>EX-99.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2a6d86fa50714cae9e6402c9f0082774_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Illumina, Inc.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of Non-GAAP Financial Guidance</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future performance and financial results are subject to risks and uncertainties, and actual results could differ materially from the guidance set forth below. Some of the factors that could affect our financial results are included from time to time in the public reports filed with the Securities and Exchange Commission, including </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1110803/000111080322000013/ilmn-20220102.htm" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-K</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fiscal year ended January 2, 2022 filed with the SEC on February 18, 2022, </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1110803/000111080322000021/ilmn-20220403.htm" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-Q</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fiscal quarter ended April 3, 2022, </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1110803/000111080322000041/ilmn-20220703.htm" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-Q</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fiscal quarter ended July 3, 2022, and </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1110803/000111080322000047/ilmn-20221002.htm" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-Q</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fiscal quarter ended October 2, 2022. We assume no obligation to update any forward-looking statements or information.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECONCILIATION BETWEEN GAAP AND NON-GAAP DILUTED EARNINGS PER SHARE GUIDANCE&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year 2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current (d)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated GAAP diluted earnings per share</font></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$0.03 - $0.28</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILTI and U.S. foreign tax credits </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(b)</font></div></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.39</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental non-GAAP tax expense </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(c)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated non-GAAP diluted earnings per share </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)</font></div></td><td colspan="3" style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.25 - $1.50</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-GAAP net income and diluted earnings per share exclude the effects of the pro forma adjustments as detailed above. Non-GAAP net income and diluted earnings per share are key components of the financial metrics utilized by the company&#8217;s board of directors to measure, in part, management&#8217;s performance and determine significant elements of management&#8217;s compensation. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing our past and future operating performance.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount represents the impact of GRAIL pre-acquisition net operating losses on GILTI and the utilization of U.S. foreign tax credits.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incremental non-GAAP tax expense reflects the tax impact related to the non-GAAP adjustments listed.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amounts assume that the existing R&#38;D capitalization requirements are not repealed and, as a result, reflect an impact of approximately $75 million.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div><font><br></font></div><div id="i2a6d86fa50714cae9e6402c9f0082774_4"></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RECONCILIATION BETWEEN GAAP AND NON-GAAP OPERATING MARGIN GUIDANCE&#58;</font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year 2023</font></div></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated GAAP operating margin</font></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated non-GAAP operating margin </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)</font></div></td><td colspan="3" style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8%</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year 2023</font></div></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Core Illumina GAAP operating margin</font></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Core Illumina non-GAAP operating margin </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)</font></div></td><td colspan="3" style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</font></td></tr></table></div><div style="margin-top:13pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-GAAP operating margin excludes the effects of the pro forma adjustments as detailed above. Management has excluded the effects of these items in this measure to assist investors in analyzing and assessing past and future operating performance, including in the non-GAAP measure related to our Core Illumina segment.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i2a6d86fa50714cae9e6402c9f0082774_78"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:13pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">RECONCILIATION BETWEEN GRAIL GAAP AND NON-GAAP OPERATING LOSS GUIDANCE&#58;</font></div><div style="margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year 2023</font></div></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GRAIL GAAP operating loss</font></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(808)</font></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GRAIL non-GAAP operating loss </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)</font></div></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670)</font></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:13pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP operating loss excludes the effect of the pro forma adjustment as detailed above. Management has excluded the effect of this item in this measure to assist investors in analyzing and assessing past and future operating performance related to the GRAIL segment.</font></div><div><font><br></font></div><div id="i2a6d86fa50714cae9e6402c9f0082774_7"></div><div style="margin-top:13pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RECONCILIATION BETWEEN GAAP AND NON-GAAP TAX RATE GUIDANCE&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year 2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current (b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">If repealed (c)</font></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated GAAP tax rate</font></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP tax adjustments </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated non-GAAP tax rate</font></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-top:13pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-GAAP tax adjustments reflect the tax impact related to the non-GAAP adjustments listed above in our &#34;Reconciliation Between GAAP and Non-GAAP Diluted Earnings Per Share Guidance.&#34; Management has excluded the effect of these items in this measure to assist investors in analyzing and assessing past and future operating performance.<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts assume that the existing R&#38;D capitalization requirements are not repealed and, as a result, reflect an impact of approximately $75 million.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> <br>(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts assume that the existing R&#38;D capitalization requirements are repealed.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ilmn-20230109.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8b48f99a-e037-4ffb-98e5-fea41bbc6a7b,g:8aa18fbb-c04f-4d51-b673-e25049429cb3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ilmn="http://www.illumina.com/20230109" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.illumina.com/20230109">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ilmn-20230109_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ilmn-20230109_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.illumina.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>ilmn-20230109_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8b48f99a-e037-4ffb-98e5-fea41bbc6a7b,g:8aa18fbb-c04f-4d51-b673-e25049429cb3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_ba98323a-61d5-48d1-bc1d-1fefae4821bd_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_cff38ea8-68ce-4529-a058-f4ebdb7406de_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_dcca40d2-1956-412d-b10d-60750e905f3e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2842a244-e77e-4fef-b7ca-c6e90bf65faa_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3154e420-2ccc-4367-b12b-f95ee4c2117c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_21606e41-1ecf-4910-abb5-b01360115848_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_63b16338-1ec2-4c50-9a71-44b242784904_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b1847770-0c00-415f-a225-93740f5cca64_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_30290408-6fa5-45ce-8824-ede0a13429e8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_28342896-31f8-48b7-aea5-937f99b5d005_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_38e26d39-9ce3-4379-b335-d80c8def6715_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_8c348170-985b-4bc0-8851-99c4180770dd_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d8b4da43-ecb9-438c-bb94-f31b4f03b8b7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8a2b6ee3-d997-436e-ba37-47fbc45d3e7f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5d74a83e-bf47-4f8d-8caf-e8f98f92f5c5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_da9bff85-dcf9-47fd-91a5-498711f4b479_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_706ebefe-0b55-4f3e-87d4-c1df18fdb9a2_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_76c0f488-e02e-4bfe-b9a2-cf6f8af97744_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_abbfadbb-099d-45db-aa0b-9cef86b0c016_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_133594ff-c5a3-424e-96c4-9121073ff7d8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9b3e745f-5188-463d-873e-058196ecd42c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_064f8343-9d3e-483c-bee4-a376479b5230_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>ilmn-20230109_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8b48f99a-e037-4ffb-98e5-fea41bbc6a7b,g:8aa18fbb-c04f-4d51-b673-e25049429cb3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.illumina.com/role/Cover" xlink:type="simple" xlink:href="ilmn-20230109.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.illumina.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b3b1d316-3e7a-4785-af4a-dd38bb2a4658" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_DocumentType_b3b1d316-3e7a-4785-af4a-dd38bb2a4658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_db9298fe-ff27-4847-9945-8c05a2bc7eb2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_DocumentPeriodEndDate_db9298fe-ff27-4847-9945-8c05a2bc7eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_257caada-8c21-44c9-a3b0-b23f619a1ad8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_EntityRegistrantName_257caada-8c21-44c9-a3b0-b23f619a1ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4c5e21f4-36fc-48bd-bddf-d2f8c5370a35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_EntityFileNumber_4c5e21f4-36fc-48bd-bddf-d2f8c5370a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f38704fa-1126-4e9f-972d-ff59c849835e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f38704fa-1126-4e9f-972d-ff59c849835e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_7dcbe435-78f3-409b-8600-3ac166c9ab4d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_EntityTaxIdentificationNumber_7dcbe435-78f3-409b-8600-3ac166c9ab4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_52bd8ec2-5ebb-4422-867d-f53700d595cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_EntityAddressAddressLine1_52bd8ec2-5ebb-4422-867d-f53700d595cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_bb3cae10-3db1-4c31-aa9f-e9d264ee55eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_EntityAddressCityOrTown_bb3cae10-3db1-4c31-aa9f-e9d264ee55eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_00c2380d-40d6-4caa-b844-2148fd901ddd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_EntityAddressStateOrProvince_00c2380d-40d6-4caa-b844-2148fd901ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3e71eff9-bb8d-405f-8b14-291429709e86" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_EntityAddressPostalZipCode_3e71eff9-bb8d-405f-8b14-291429709e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1db98e6a-2d73-4a9b-bb33-1d32779f80fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_CityAreaCode_1db98e6a-2d73-4a9b-bb33-1d32779f80fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c75739dd-4355-456c-b0e1-4b2dce60843a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_LocalPhoneNumber_c75739dd-4355-456c-b0e1-4b2dce60843a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_409dc7fc-73dc-40a5-923c-179d7c892e86" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_WrittenCommunications_409dc7fc-73dc-40a5-923c-179d7c892e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_dfa2b13e-c75f-42a8-827e-739d0cdc125b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_SolicitingMaterial_dfa2b13e-c75f-42a8-827e-739d0cdc125b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_051fefef-c81c-4d79-8879-9f63e4cfbb45" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_PreCommencementTenderOffer_051fefef-c81c-4d79-8879-9f63e4cfbb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_b594d335-a532-44de-8ef1-76c2296b5fde" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_b594d335-a532-44de-8ef1-76c2296b5fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_49a39550-e230-4f3c-8475-c96773a029b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_Security12bTitle_49a39550-e230-4f3c-8475-c96773a029b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ebd895f8-4c01-4cf4-b4b3-bdce21cc0c72" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_TradingSymbol_ebd895f8-4c01-4cf4-b4b3-bdce21cc0c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5fa35816-856e-41b8-909d-5f54d4e19b8d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_SecurityExchangeName_5fa35816-856e-41b8-909d-5f54d4e19b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_76c36e5b-bd07-4831-97e4-9edff39d0516" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_EntityEmergingGrowthCompany_76c36e5b-bd07-4831-97e4-9edff39d0516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b458ed3d-11a0-49dc-b601-1a64ab18862d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_EntityCentralIndexKey_b458ed3d-11a0-49dc-b601-1a64ab18862d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8c4b9a65-c876-4a0e-bbfd-0f3f73b83668" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a3a27603-e321-4751-8c86-475b82c072cb" xlink:to="loc_dei_AmendmentFlag_8c4b9a65-c876-4a0e-bbfd-0f3f73b83668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ilmn-20230109_g1.jpg
<TEXT>
begin 644 ilmn-20230109_g1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !< 7 # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]3_:CZT=J
MQ/%GB[3O!NEM?:E*4CSM1%&7D;&0JCUKGJU84(.I4=DNIK3IRJ24(*[9N<TG
M/TKSGPS\<M"\2:I'I_EW%C-,=L37(4*[$\+D,<$UZ-]:Y\+C</CH.IAIJ278
MVQ&&K867)7BXOS*6K:UI_A^Q:\U2^MM.LU(#7%W,L48). "S$#)-8UI\3O!U
M_=06MKXMT.YNIW6**&'487=V8@*J@-DDG@ >M<'^UK_R1/5/^OBW_P#1JU\:
M_"7_ )*KX,_[#5G_ .CTKN2.4_2VJVH:E::39RWE]=0V5I"NZ2>XD6-$'JS$
MX ^M6:\^_:"_Y(OXL_Z\S_Z$M(HUO^%M>!_^AS\/_P#@T@_^+KJZ_*>OU8IB
M"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@!*\7_:2TRZN+'1KZ.)GM;9I4
MF91]POLVY] 2IY^GK7M & !44]O'<PO%+&LD;@JR,,@@]C7E9I@5F6#GA6[<
MW7T=_P!#MP.*>!Q,,0E?E_X8^+]&TN[UK5+6RL8VDNIG"QA,YSGJ<= !DY[<
MU]I19\M>QQ6?IGAG2=%E>33]-M;*1QAFMX50L.N.!6G7C</9$\DIS4I\SE;T
MT/3SC-O[4G!J'*H_J>.?M:?\D2U3_KXM_P#T:M?&WPE_Y*KX,_[#5G_Z/2OL
MG]K3_DB6J?\ 7Q;_ /HU:^-OA+_R57P9_P!AJS_]'I7V"/G>I^EM>>_M!?\
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M2=6N9 ^HJ#:WA!_Y;1G!8\  L-KX XWXKT&I*/D?_AN74/\ H4;;_P #F_\
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M%=Z=<ZS."2;F\NY%;GL%C*K@>XS[FJT%J?/NF_MB?$&PSYYTO4?^OFT*]O\
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M44AA7EG[17_(DV__ %^)_P"@M7J=>6?M%?\ (DV__7XG_H+5\_Q!_P BNO\
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MEX._[#-G_P"CTJD3U/TOKXH_;8_Y*II7_8%B_P#1\]?:]?%'[;'_ "532O\
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M/JCQ7X:L%\>Z&3_S\J/SX'ZU]>#[OX5\@?#G_D>M#_Z^X_YU]?K]VOD^!/\
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M-_#(\9^$=7T)K@VJW]N]N9PFXIN&,@9&?SKYW_X89M?^APF_\%Z__'*^I**
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@Z])JD=]"L3P-;"(!E;*MG>>Q;MWKUZBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140538176325280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  09,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Illumina, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0804655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5200 Illumina Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">202-4500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01&#160;par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ILMN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001110803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>ilmn-20230109_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ilmn-20230109.xsd" xlink:type="simple"/>
    <context id="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001110803</identifier>
        </entity>
        <period>
            <startDate>2023-01-09</startDate>
            <endDate>2023-01-09</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV80L2ZyYWc6YTI4MTc2NjI5OTg0NDc2ODg2YzAzNDc5MmI1YmVjNGMvdGFibGU6MzRkMGE2ZTEwYTQwNDk5OWFlMGFhMDQwNzNjMTI4MzEvdGFibGVyYW5nZTozNGQwYTZlMTBhNDA0OTk5YWUwYWEwNDA3M2MxMjgzMV8xLTEtMS0xLTE2MjQyNg_ea8e49d4-143f-40fa-a276-b23c3fc0ee7b">0001110803</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV80L2ZyYWc6YTI4MTc2NjI5OTg0NDc2ODg2YzAzNDc5MmI1YmVjNGMvdGFibGU6MzRkMGE2ZTEwYTQwNDk5OWFlMGFhMDQwNzNjMTI4MzEvdGFibGVyYW5nZTozNGQwYTZlMTBhNDA0OTk5YWUwYWEwNDA3M2MxMjgzMV8yLTEtMS0xLTE2MjQyNg_38becb61-cdb2-4195-be7a-067332bbaaba">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml84Mg_aaab4603-f37b-4996-aeaf-de7e628bf4ad">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8yMjI_2d948ad3-ea7f-4f71-98f9-80e1ea933f2a">2023-01-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8yMjg_cde71004-901d-42f6-9179-1e3e46033aeb">Illumina, Inc.</dei:EntityRegistrantName>
    <dei:EntityFileNumber
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8yODc_0c2e294b-72a1-4990-90e6-ae8b121b9928">001-35406</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGFibGU6ZjVkMDc4ZWEwNmI5NDhkNTg2M2ZmM2I2YmJkZmE4ZTAvdGFibGVyYW5nZTpmNWQwNzhlYTA2Yjk0OGQ1ODYzZmYzYjZiYmRmYThlMF8wLTAtMS0xLTE2MjQyNg_fb918ec4-6333-4041-8e0a-dc3fbb24baab">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGFibGU6ZjVkMDc4ZWEwNmI5NDhkNTg2M2ZmM2I2YmJkZmE4ZTAvdGFibGVyYW5nZTpmNWQwNzhlYTA2Yjk0OGQ1ODYzZmYzYjZiYmRmYThlMF8wLTItMS0xLTE2MjQyNg_5e0f000e-5591-49f1-98c3-cffc3710508b">33-0804655</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8zMTc_d360f3db-a32f-4099-a2a9-b2c32f0e2b56">5200 Illumina Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8zMjE_163cab63-3522-4200-9767-cd0df520e512">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8zMjU_0f754a16-2570-4f54-a81f-46292df5d99b">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8zMjg_0596d85c-e604-4f47-8067-e62f04eddd65">92122</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8zODU_650e3e8c-86df-4e78-9e9a-b667fa34d8b4">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8zODk_eb41857f-c372-45e6-97fa-a2db01e02b14">202-4500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8xNjc4_a22ba31b-65bf-4d00-9cd1-a29b7f6e6c56">false</dei:WrittenCommunications>
    <dei:WrittenCommunications
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml82ODU_90ede0c5-81d8-474a-8a1e-c53bcbabda4d">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8xNjc5_a1cc79eb-be1c-425f-b340-33b39c7f87fe">false</dei:SolicitingMaterial>
    <dei:SolicitingMaterial
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml83Nzg_23946e7c-24f1-4f44-bb76-87f7f149fbd6">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml84NzI_d5a5408c-71fa-405c-a155-86c78759056e">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml85ODI_b7eaa39f-ebfb-4cfa-8baa-3e3a6c14af90">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGFibGU6MmI0YjE3ZDIyZjE4NGM1YWEwYmJhNTJmMmI4OTA1NGQvdGFibGVyYW5nZToyYjRiMTdkMjJmMTg0YzVhYTBiYmE1MmYyYjg5MDU0ZF8xLTAtMS0xLTE2MjQyNg_5ce7d720-0041-4f6b-ad35-d9d3d7d3d7dc">Common Stock, $0.01&#160;par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGFibGU6MmI0YjE3ZDIyZjE4NGM1YWEwYmJhNTJmMmI4OTA1NGQvdGFibGVyYW5nZToyYjRiMTdkMjJmMTg0YzVhYTBiYmE1MmYyYjg5MDU0ZF8xLTEtMS0xLTE2MjQyNg_6993fd33-ea8d-4d66-93ef-76a26a98cc64">ILMN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGFibGU6MmI0YjE3ZDIyZjE4NGM1YWEwYmJhNTJmMmI4OTA1NGQvdGFibGVyYW5nZToyYjRiMTdkMjJmMTg0YzVhYTBiYmE1MmYyYjg5MDU0ZF8xLTItMS0xLTE2MjQyNg_ffe3a804-0a9e-4b47-bae9-8e11dcbde1ea">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzRkMjg1MjJkNDQ1MDc4MDQxZDJmYTExN2M0MDA1L3NlYzpkZDM0ZDI4NTIyZDQ0NTA3ODA0MWQyZmExMTdjNDAwNV8xL2ZyYWc6ZjZlNDA3NzdhMzJhNDAzM2I4ZDY3Y2ZlZDM1NjE0NzIvdGV4dHJlZ2lvbjpmNmU0MDc3N2EzMmE0MDMzYjhkNjdjZmVkMzU2MTQ3Ml8xNDE3_397b8f98-fe9d-47b3-9929-0fb2732161b8">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ QI@J5JK$(A8S 0  (@(
M  \   !X;"]W;W)K8F]O:RYX;6R-4=%NPC ,_)4J'[ 6M"$-45Y VY"F#8V)
M]]"ZU"*)*\>%C:^?VZH:TE[VE-S9NMQ=%A?BTX'HE'QY%V)N:I%FGJ:QJ,';
M>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L,9KD8M;:<W@(2* 0I*-D1>X1+
M_)UW,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU75Z(\4I!K-L53,[E9C(,]L""
MQ1]ZUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H%7I")\!K*_#,U#88
MCIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HD<%U!D.LL8DF"=9#;E9T!N[R
MZ .;<L@F:NJF*9ZC#GA3#O9&3R54&*!\4YFHO/93;#GICEYG>O\P>=0>6N=6
MRKV'5[+E&''\GN4/4$L#!!0    ( ,:8*E8D'INBK0   /@!   :    >&PO
M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN
M$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NT
MBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X\ \P
MO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].M.=Y
M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " #&F"I699!YDAD!  #/ P  $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ QI@J5IE<G",0!@
MG"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " #&F"I6*9)SP#D$  !P$   &               @($,"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ QI@J5I^@&_"Q @
MX@P   T              ( !>PP  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" #&F"I6EXJ[',     3 @  "P              @ %7#P  7W)E;',O+G)E
M;'-02P$"% ,4    " #&F"I6JL0B%C,!   B @  #P              @ %
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ QI@J5B0>FZ*M    ^ $
M !H              ( !H!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ QI@J5F60>9(9 0  SP,  !,              ( !A1(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  SQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ilmn-20230109.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.illumina.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ilmn-20230109.htm">ilmn-20230109.htm</File>
    <File>ex991transcriptjpm2023.htm</File>
    <File>ex992reconofprelimnon-gaap.htm</File>
    <File>ex993reconofnon-gaapguidan.htm</File>
    <File>ilmn-20230109.xsd</File>
    <File>ilmn-20230109_lab.xml</File>
    <File>ilmn-20230109_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ilmn-20230109_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ilmn-20230109.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ilmn-20230109.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ilmn-20230109_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ilmn-20230109_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ilmn-20230109.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ilmn",
   "nsuri": "http://www.illumina.com/20230109",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ilmn-20230109.htm",
      "contextRef": "idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.illumina.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ilmn-20230109.htm",
      "contextRef": "idb29eaba0fb24738afe4971c2803c83b_D20230109-20230109",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.illumina.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001110803-23-000003-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001110803-23-000003-xbrl.zip
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MMF3M&A%Q^NME+EL)HM4EA9TI\&M9C[RN4W,"#_D1N"G"*K>8I\HR^5@T''9
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MS0GTH[<<OF,J>+4::D6P(,9MHWB RV'+@NBB1CP/81T]PT/PFQ!8[H++B5R
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MI:E=3$4I,%=3_< 4DT$5\660S@BLU+(411ZS8,.B 2_K790HY )JG;+@X[/
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M]<@*ZL9]"6T2$TLP^4?!&O>UGJ$E<Q"*^9X+Z70KDXVP$Y-CW.!JARQI788
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MOGXQ2+:TQ6+G%*09+FX8>FI8@P9 XB>YH!T5GE]C[K\,I=UWMWNA4A_M/^C
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MW4<R&3UC"<MP 86F[ ",;I-/PPC<%2STZZ]?=1;EP9^^WW;R4;%UZ9\S5/(
M=FFI7'S&B!/C/H:7T12"0T<N],@:+=.JON]0#'YR!TM>K_4@PB5[DT2_8Q]6
M!,#::EC1-UHGC-_P6R95<[^KQEY!GX^W;-]J1J204CAH4-_1CO#DW>_,X5F5
M!5*N";#YOKI6;[['#J;(52M  I$HZV>OP+62ALEOE&I^#%[\Z\&+CYKO_U/S
ML??(SBU-:9A[FEV*$>V;*"0QR];WZ#+;:)02"I5A#[L]++#RR[-2?Z*]$10I
MEW459H>L@$(_++Y7UOH2Z[*;UL<<C$;]X'W.4<7':695 ]#NFA"I*(E8_$_]
M-,)E&\3%ZO"]X*6=D"1H@AE+7R2YQTN+A$U1_S26J[V6'1"0Y*OWZ:?:LQ9]
M\W7&P%.5*[3U2.^K8CH4D,3D;@[YQ28/UX7'E]@EAL %37[SA2;+,1?_CH<>
MT!IO3,"PH>_?P9[^/_);!0@8%-,;* AWRJ*=3^@Y?W_(?OIC"+>%,CVF5]CY
MAN+^+B#K)*^F%_$4$86[FW,;JUT-?>A-U%8$/6^6\)\5AF*5IR&$%FQ2[[19
MF;S20ATGRKX!*"&KMHD3P!,<_92G25K<:9*-MX@]HE;QW?[!#H@L;:F%[P^8
M,*Y*>97&K-F?4S=^/R=&.^XVKPQT%R^+"07@Q),3F)3LONXXMX7IJ#3]E.X^
MB6>B,)A[CB8Y%3L12Y/^IPY&@^3[8R(\CLY$X/Z4 ! ATEMV-%X06Z>-Y27"
M1Q%2?9?T5"6K#5XL-#%Z!_AC%V.Z4P;F)>I!T->';R9=[=1FH:[*]=H>NI+S
M%B)=AW*0W:/1;/PD^^K%2X7?P<8IXA5_^ U;MH8>IB&:A6HNN(,R- "_^6A@
M&<)%5 \;1\$O#P57([B/>NP&.,5=C4#N8D6O?[CR/0E'R+&=67TTM_YHY#@O
MFT5U3#A3=$4V6#-C'#4J<A03SCRB+[@-,  C&%:,'C_U=S#KC;':(S2H4J-!
M@^K;Z#2^D^'1O=+?$A]!@:GP&_<Q4)2)81MH4NV'NZU.-JCX.TIEQZT2?%-H
MK9@1L2BZ96!_">^8^L:/"2XCWO]4E"MG=;6Q PG;V%H7JS<)]*9,JUL:6+B\
MJ3AT'ZH1D-@!VZII>-\M=CL(]X.0O[_3B^A>F^E^\K!&H_NT@* XPS6XGWA?
M=T(SS3K :-G9R6XQ]@TSD_/T[454[0ME*9DALS34!NS"0U>#;$'V3B95JIER
MN2S=@M>X6+/<U\!-,^[697I%N7)$CA[Z0@,3WT8JOOBNY%/2?K=IKT4B_ZK]
M.#1<V7E7":;,+G7>00,?(S6'Q (^,&W'SH#<YY-1NW=0S<GY>7KG8EH'2V+Q
M*;T<,D^&1C_D#AJZM\9^8QJ/($05G$6^U:JZX)\:I2X&2)9Q98<6A'1Z;244
M/+TCC9 #C[OQF'X:D/1$&U;KKL-[0@'-728H?I'WO38(4:N%&F/'QKQC68HK
M\S/2AA\)*Y?=TD2REFXVXU5.4H=ZIVVA%K#7S:T'U1VT: U! <)F0@^6><[D
MB,><XI;AQH=<3%_R6(0\9DVQS5S5$9:OC6(-O&A)"E^9H<!/IK;1<EG+,'8J
MHA\:W,]?&<A+<JQB@<JVZ<9E($2 L.'R_54?/CRGB-[4AT;1G^%TQ^31X]>#
M+^(*#U-\B@)N<>^RN=<K^UZ;H/ER[J%>Y[&1<[CG=.-MVU'13%%V[;".:,.4
MYI7Q$/0O$?*G,C#*OFY9_:R?[=8KDI@K->"5)..FD9:QDYTL6'9(+V=')4<.
MZNYV3K$>PYF)WI9S20Z>'%#VDQ$YE(=!^Q^^6_?-P-8TUFHT)"9Y1>X,42V?
MC\HSX;0!32SOB8E?ZUTA>7MMQ5!&A6JDXT.[^Y5!\I@XLI!5Z.T8>\58O F]
M59MXO<=#-(:Y:JPPQ%5KY27U\.*E>;L-P%B=!7NT.WC<P ?DR5U1+7_'/ 9Q
MYLBD$ MPJ\UX"9$RG.L!;_D'@\2%V?7-4)4Y>CFUK&O*36U^?Y99"V;3>*BP
M/?"@Q0<@*K]N%'\_R=;L1_^1BO^P+9UFH^HM(6#5%+@O0HNQ@SL9NM$PM.,;
M!(2F^#YW:J!QS93MA\E'%<0C;:'("_7>P[U4"$W%!AVI@NMB&Q1_E1U>HZE;
M:SU/XPS] R=:1_[DF"8E4!Q/CR,*D:Z317RL% P8>ERVU[3!N=82U*Y4JRFQ
M:U]Z&&9R62@]L%7^,QO$A9B_[]'S8X+80X;IO2]*NW$;9Y>C^T6EH+S<M]#1
M[*"NU;;C()CB;F)#?A]>!Z$E/HE*JS[D([0^+FQ*KKE6KX9#C\C01GV_H$S[
MUZ&U+,!9J)<(E[IC.T/,/*1$=B]/LZS*F,;T+A=+U(@O&-K]G?W';Q?Z&'<Y
M"%'] 2@^WU)">\OK[9?H!Z'API<AVMW],CCW*\7UB9&[M^4I;&X  D<=HOZ7
MV?O".0SRZ T1/IW\_'+_CNK8:<D#:D)7V>#Y&RS:)+7>E6F=]F;:Z[=A&1 =
MU,*M<=$[G-UN4RY$;QRXE?0!.03_M&L\>)AW7"G.;G.KM?Q+;U!/+MN(AL 5
M3L4N/N;;QK77.6%1<XCE6Q?;/J],5(JJG-_0C\3U@]:N(NAZ;>^GEZC?-TF6
M<_K;T-10@5I.F]G[I'ZR%FTGL+TO"Z1SUW &30/LFKV-5RV3:#&TOZ$V"9_K
MCF[CG=)J;I0+=]0I>B5>#. O$>/[_%5BLPHW+!SX)=L7:<Z#0D(3M.@75+'[
M)[X%P-54-JCIKIW&$>.VZ+"5/@KER^_]5;SCT*MJU39>D>:W--WH<0L[3):-
M0$;7 .QTP;'SHP#+:R,C (MJ(=UE1&.7-\Z0%$$>WD.=_O*'6,.3[%>Z649V
ML[S*-6&J":!NE*X$XWBNF6E-!\%/^Y3\6T2\?Q!C$M1RHFXG4(ZNABCH:%I_
M+-H-P$I$K,T+.F0F9_#[6ZX19Q'\:UQ;CI>)-7'@I)]<;Q(N&4QRQ;C8Q9IM
MD8)2K$RD)KL&Y5\4/D':X;H_MVPJ;;#[>Y7SCT=Q^YQ]W>V*(CA<'KGNDR$'
ML?^_9X\=PASO"=H"[ *3"N4#E6,DOD6CBEYK[QC5#!?LX;38PYKQ=F07<%<-
M_J -!4MN>N#>P2,$_.5?RWY5_?W_ 5!+ P04    " #&F"I6'2RGM 8,   B
M>0  '@   &5X.3DR<F5C;VYO9G!R96QI;6YO;BUG86%P+FAT;>U=ZU?CMA+_
M?O\*E>VVN^<0/Q/R@.6>%%*:7A9VL_3L[:=[%%M.5!S+E60@_>OO2'82DP<$
M"'F0[ <V00_/C'Z:&<V(\=$/IY<G5W]^::"N[(7HRQ^_G#=/T%[!-+^[)Z9Y
M>G6*?KOZ?(Z*AF6C*XXC025E$0Y-LW&QA_:Z4L8UT[R]O35N78/QCGG5,M54
M13-D3!##E_[>\9'Z#?PDV#_^U]$/A0(Z95[2(Y%$'B=8$A\E@D8=]-TGXAH5
M"EFO$Q;W.>UT)7(LQT7?&;^F-SAMEU2&Y'@PSY&9?C\R]4..VLSO'Q_Y] 91
M_],>+1\$MA]@OUJL.,6V4ZY6#RS+;_N66R16M83_9P.1)G1/QPC9#\FGO1Z-
M"EVBGE\K.D:Y%,O#6^K+;LVVK/=[NNOQ4< B"<_C,#[]F$XS,9DD=[* 0]J)
M:AX03/A>.G;0[K&0\=H[2_\[5"V% /=HV*_]7.<4AS_O"Y!^01!.@[19T'\(
MD )4Z:^W*:5E&!W2B PH3VEMAF$"[.!]U(P\XSZI>8XQ[P#3DL4U%^9=+<U?
M. FI(IKW48N())0"L0!=QH1C!4*!"NB"186S>OW+9G#T(8EPXE/ ^\>7$CP%
M<D,X+IJ9XC@SCF+F,N$(EB)@O(<CCR <^2B U8H\F!KQ;,$P)T@D[;^()Y%D
MB%-Q+737!,9PB6DD*1'[^E?8DTENJ,>2T$<^#0+"40^TA*(Y[*. LQZ278+B
M'$ &@P21"$B27=0F(;LUT#?6(PHV:D  3V!<P&<LL^DQS ZD,6!F.O$T\L+$
M!PV5/I;";,"'_I]&*1E).Z0>#(KAN0*F":'W+0425.LWXB6<*B8UCXT[KXNC
M#@'=UNM1(0#'^]DSE (<K.B,90R"!2]CBB^?>"S=4[4D\@E7O0!G&'4Y"3YI
M)2\R+2^(9W38C4GO_NTS[Y-9YUZ7WA!A$K^#N>ECB4W;MJV*Y9I </;1<13U
MMFO2L!<50)D[EFTY!IB%O55S^2O@%]E6X3]')CY^1/ROL(L46%-L4N$!]/H$
M<T0B!;C?<90H:#O[ROPY$\!JG" 6H5])F^MN=B7MM_^V0>38.1 5+7>M0/1U
M/4#T-P "U&6&HWK,:8C<K4!',8^.\@X=CZ/C]P1,ZA <RD2];8"41P !IVR]
M;-!: N02?*8V?,O,D(&^@Z\G!!R[4,00 ]^GHQE2;E$2@_"5*]A7<]YB[A?@
M&'BM/!LAH44=U<")Y^#Q:+]1C9OK-&*#+[QH5UW/4Z,2O&MO#BE=C7F<0U\^
MS\S(7<R<0XG;(;A^VAE%%'S ..;LCO92,?EYWSAU#+5\;VD89@YEZIK"#S#[
M@X71KG829MY"MFK:1QAXKG3D&*Q,OK..0EJ:)Y<7WR[/FZ?UJ\8I:C7@ZTGS
MO%F_:EY>H%\:5]\;C0OTI=4X;WYN7M1;?R)UR$/UBU-T<7FA3WSH\DNC!?TO
MSM#G>NNL>?'3NU+E\ F\ZI49-+<9A]U8 )Y#' M2&WPX]*F(0]ROT4CSH <=
M9I.UF92L5U-Q@1LXRU!8A>RHIO=ZVIR%#*I5HU)R5=1 PKE-^H,'9P$%0P<4
M3.E/MI7+1L4^F-EL&?;,MH>FM:M&M5*<:UI3DYR2#8(1,8X^[;E#K1EC7YU=
M:A:RM6 '\SW0U8GO5.?)T^VX(%,9+@:9U;G.Z+^FN^E/M;/4EAHB:@Y)M+%W
MW>$,-'LAH]'7_PX?X#LDP01\%LGU,X(M>GNQ-,P"FCM%^STY/)'];'?IS1<#
M0RRD/E*</"28UP?$O%&;JFTX']^_# B!_K=60)@P<YK;>@^,#OTGM68L0-C[
M.Z%<&S0)]HDJI0GFGTCQ+$0\+H<5K/MT2;A&=:6;?WGQO'3AU4*GX?T"* ,=
ME2=W,8D$^"^OZ93.V'7ML1CI<Q3/)L#,,2HK52U+AMD98[YV;VDOQI3K)- *
MT.6]!%T;I,0J):.T35JL183DB2<3/D<X_36 -9[:>:MJRS+*VZ2V3J 'D*E3
MUBP2U,^2D"BDN$W#-,&S KB1+=%C'XI&Z>,V*;)STH%CJ#> G==/PT5$RI"L
MRF@&6Z+;;-=XX;E_LY1;_O ?93<J)@( JP <7H!VRX(/6;#.C27R6:).L3H
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M+P>J.V^81EZ#0V!GTUQ^ = BT\C]YT3'IR^(?PT[2((UPB;E%D"O3S!#Q).
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M#9QE4,+@)A,[O2RM1A*2O4=@A_D6HS1_Y_,\7<,G0>F[H6G^VJ/=M:L ?M]
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M81VD]<*A>/UR!>/MVGZ_VD GV*[U?/("4$L#!!0    ( ,:8*E:-%)&K>!@
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M1)Y+N+K5N?0)7]#J5284\ZZ$;=3V@[$A\./TUBFHZDD')UV&,C>Q:\I,0(/
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M#86B6;:B';;:'Y Q;5RMSQ<DRY+YIC)WJ3ID:G6DY!_(X<RQ?P-02P,$%
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MSD31I@-MVX^I!Y6XO/]ND/WOF?J0+=ING:CF:;A>9 N@UHVL!AT6/96X,>/
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M=S_T+_WC\ <[_P=02P$"% ,4    " #&F"I65$E:2EPV  #"X@  &@
M        @ $     97@Y.3%T<F%N<V-R:7!T:G!M,C R,RYH=&U02P$"% ,4
M    " #&F"I6'2RGM 8,   B>0  '@              @ &4-@  97@Y.3)R
M96-O;F]F<')E;&EM;F]N+6=A87 N:'1M4$L! A0#%     @ QI@J5K+3%^#Y
M"@  _G(  !X              ( !UD(  &5X.3DS<F5C;VYO9FYO;BUG86%P
M9W5I9&%N+FAT;5!+ 0(4 Q0    ( ,:8*E;R([?([Q4   6G   1
M      "  0M.  !I;&UN+3(P,C,P,3 Y+FAT;5!+ 0(4 Q0    ( ,:8*E9E
M6"5G: (  &X'   1              "  2ED  !I;&UN+3(P,C,P,3 Y+GAS
M9%!+ 0(4 Q0    ( ,:8*E:-%)&K>!@  *L:   4              "  <!F
M  !I;&UN+3(P,C,P,3 Y7V<Q+FIP9U!+ 0(4 Q0    ( ,:8*E:/_*\_0 H
M !A=   5              "  6I_  !I;&UN+3(P,C,P,3 Y7VQA8BYX;6Q0
M2P$"% ,4    " #&F"I62<(F=J8&  #<,   %0              @ '=B0
K:6QM;BTR,#(S,#$P.5]P<F4N>&UL4$L%!@     (  @ )@(  +:0      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
